Paper No. 9
Date Filed: May 24, 2016

Filed on behalf of: Aventis Pharma S.A.

By:

Dominick A. Conde
dconde@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LIMITED
Petitioner,
v.
AVENTIS PHARMA S.A.
Patent Owner.

Case IPR2016-00627
U.S. Patent No. 5,847,170

PATENT OWNER'S EXHIBIT LIST 1

EXHIBIT LIST 1

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Aventis Pharma S.A. ("Aventis") respectfully submits the following current exhibit list.

Aventis Exhibit No.	Description
2001	de Bono *et al*., "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial," 376(9747):1147-54, *Lancet*, 2010 ("de Bono")
2002	FDA News Release, "FDA Approves New Treatment for Advanced Prostate Cancer," (Jun. 17, 2010, last accessed on May 23, 2016 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/)
2003	European Patent Application Publication No. 0604910 ("EP'910")
2004	European Patent Application Publication No. 0639577 ("EP'577")
2005	Reserved
2006	Reserved
2007	United States Patent No. 5,229,526 ("'526 patent")
2008	Reserved
2009	United States Patent No. 5,319,112 ("'112 patent")

Aventis Exhibit No.	**Description**
2010	Vrignaud *et al*., "Preclinical profile of cabazitaxel," 8:1851-67, *Drug Des. Devel. Ther*., 2014 ("Vrignaud 2014")
2011	Excerpt from June 26, 1996 Information Disclosure Statement submission from the File History of U.S. Patent No. 5,847,170
2012	PCT Patent Application Publication No. WO94/07878 ("WO'878")
2013	European Patent Application Publication No. 0336841 ("EP'841")
2014	Morrow & Cowan, "Antineoplastic Drug Resistance and Breast Cancer," 698:289-312, *Ann. N.Y. Acad. Sci.*, 1993 ("Morrow")
2015	Rowinsky *et al*., "Taxol: the First of the Taxanes, an Important New Class of Antitumor Agents," 19(6): 646-62, *Semin. Oncol.*, 1992 ("Rowinsky")
2016	Ojima *et al*., "Synthesis and biological activity of 3'-alkyl- and 3'-alkenyl-3'-dephenyldocetaxels," 4(21): 2631-34, *Bioorg. & Medicinal Chem. Lett.*, 1994 ("Ojima I")
2017	Kingston, Ch. 15, "*Recent Advances in the Chemistry and Structure—Activity Relationships of Paclitaxel*," in Taxane Anticancer Agents, ACS Symposium Series Vol. 583, pp. 203-16

Aventis Exhibit No.	Description
	(Georg *et al*., eds., 1994) ("Kingston 1994")
2018	Ojima *et al*., Ch. 19, "*Syntheses and Structure—Activity Relationships of New Taxoids*, *in* Taxane Anticancer Agents ACS Symposium Series Vol. 583, 262-75 (Georg *et al*., eds., 1994) ("Ojima II")
2019	Commerçon *et al*., Ch. 17 *Practical Semisynthesis and Antimitotic Activity of Docetaxel and Side-Chain Analogues*, *in* Taxane Anticancer Agents, ACS Symposium Series Vol. 583, 233-46 (Georg *et al*., eds., 1994) ("Commerçon")
2020	Wargin & Lucas, "The clinical pharmacokinetics of vinorelbine (Navelbine)," 21(5 Suppl. 10):21-27, *Semin. Oncol.*, 1994 ("Wargin")
2021	Robert, "Epirubicin: Clinical Pharmacology & Dose-Effect Relationship," 45 (Suppl. 2):20-30, *Drugs*, 1993 ("Robert")
2022	Rahman *et al*., "Comparative Pharmacokinetics of Free Doxorubicin & Doxorubicin Entrapped in Cardiolipin Liposomes," 46(5): 2295-9, *Cancer Res.*, 1986 ("Rahman")

Aventis Exhibit No.	Description
2023	Thürlimann *et al.*, "Dexverapamil to overcome epirubicin resistance in advanced breast cancer," 121 (Suppl. 3):R3-R6, *J. Cancer Res. Clin. Oncol.*, 1995 ("Thürlimann")
2024	Holmes *et al.*, Ch. 3, "*Current Status of Clinical Trials with Paclitaxel and Docetaxel*," in Taxane Anticancer Agents, ACS Symposium Series Vol. 583, pp. 31-57 (Georg *et al.*, eds., 1994) ("Holmes")
2025	Stierle *et al.*, Ch. 6, "*Bioactive Metabolites of the Endophytic Fungi of Pacific Yew, Taxus brevifolia*," in Taxane Anticancer Agents, ACS Symposium Series, Vol. 583, pp. 81-97 (Georg *et al.*, eds., 1994) ("Stierle")
2026	Guéritte-Voegelein *et al.*, "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity," 34:992-8, *J. Med. Chem.*, 1991 ("Guéritte-Voegelein")
2027	Stewart, *Lung cancer resistance to chemotherapy in* Lung Cancer: Prevention, Management, and Emerging Therapies, Current Clinical Oncology 331-93(Humana Press, 2010) ("Stewart")

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.